Pfizer (PFE) Short term Debt (2009 - 2026)

Pfizer has disclosed Short term Debt across 18 years of filings, most recently posting $3.9 billion for Q1 2026.

• In Q1 2026, Short term Debt fell 12.98% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $3.9 billion (down 12.98% YoY), while the FY2025 annual figure was $3.2 billion, down 54.59% from the prior year.
• Short term Debt climbed to $3.9 billion in Q1 2026, from $3.2 billion in the prior quarter.
• Over the last five years, Short term Debt for PFE reached as high as $11.9 billion in Q2 2024 and fell as low as $645.0 million in Q2 2022.
• The 5-year median for Short term Debt is $4.3 billion (2025), against an average of $5.4 billion.
• Annual changes were most pronounced in 2022 — Short term Debt tumbled 85.18% — and 2023, when it jumped 549.3%.
• A 5-year view of Short term Debt shows it stood at $2.9 billion in 2022, then soared by 251.44% to $10.4 billion in 2023, then slumped by 32.89% to $6.9 billion in 2024, then slumped by 54.59% to $3.2 billion in 2025, then rose by 23.34% to $3.9 billion in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $3.9 billion, $3.2 billion, and $4.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.